Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Active Enzyme | ALPI Recombinant Protein (Wild-Type & Mutants); HEK293 expressed, >95% purity, <1 EU/µg endotoxin, verified sequence. | View ALPI Products |
| Isoform Counter-Screen 1 | ALPL (Liver/Bone/Kidney) Recombinant Protein for selectivity assays. | View ALPL Products |
| Isoform Counter-Screen 2 | ALPP (Placental) Recombinant Protein for off-target binding evaluation. | View ALPP Products |
| Gene Delivery | ALPI Lentivirus / Promise-ORF for stable cell line construction. | View ALPI Products |
| Benchmark Ab | Anti-ALPI recombinant positive control for PK/PD assay development. | View ALPI Products |
| Validator | ALPI siRNA Set (3 unique sequences) for knockdown verification. | View ALPI Products |
| Related Target | TLR4 – LPS co-receptor; ALPI dephosphorylates LPS to prevent TLR4 activation. | View TLR4 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (ALPI vs ALPL vs ALPP) | Ortholog Panel: ALPI, ALPL, ALPP with distinct N-terminal truncations; >95% purity, mass spec verified. |
| Preserving Enzymatic Activity & Glycosylation | HEK293 mammalian expression ensures native PTMs and active conformation. |
| LPS Binding Contamination Risk | Endotoxin <1 EU/µg (LAL tested); essential for ALPI-LPS interaction assays. |
| GPI-Anchor Dependent Conformation | Lentivirus stable cell line preserves native membrane topology for flow cytometry/cellular uptake. |
| Lack of Robust Pharmacokinetic Controls | Recombinant anti-ALPI benchmark antibodies available for reliable ELISA/SPR development. |
Key Mutations and Variants
According to UniProt (P09923), two missense mutations have been documented in dbSNP:
- rs7559279 (VAR_050524)
- rs1047223 (VAR_011816)
These variants may alter ALPI enzymatic activity and are relevant for engineering isoform-specific or stability-enhanced enzyme replacement therapies.
Live ALPI R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The ALPI therapeutic landscape is dominated by enzyme replacement strategies targeting lipopolysaccharide (LPS) detoxification. Following Pfizer's acquisition of AM-Pharma and its recombinant alkaline phosphatase (recAP) program, the field has validated ALPI's role in treating inflammatory conditions. While Phase 3 results in sepsis-associated acute kidney injury (SA-AKI) have shown mixed efficacy, development continues for ulcerative colitis and other barrier dysfunction indications. The focus is shifting from bovine-derived enzymes to fully recombinant human ALPI, with the next wave targeting oral delivery for localized GI diseases and engineered variants with extended half-lives for systemic administration. Small molecule inhibitors are also pursued for calcification disorders requiring isoform-specific targeting.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement (Biologic) | Pfizer (AM-Pharma), Protalix, Bolder BioTechnology | Sepsis, Ulcerative Colitis | Catalytic Activity Standardization (Need high-purity ALPI with native glycosylation) |
| Small Molecule Inhibitors | Novartis, Alexion | Hypophosphatasia, Vascular Calcification | Isoform Selectivity Panel (Need ALPI vs ALPL discrimination) |
| Oral Formulations | Synthetic Biologics, Academic spin-offs | Ulcerative Colitis, Enterocolitis | Protease Resistance Assays (Need high-purity mutant ALPI) |
| Gene Therapy / Overexpression | Various Biotechs & Academic Consortia | Microbiome Modulation, Intestinal Barrier Repair | In vitro validation (Need lentivirus for stable ALPI cell lines) |
| Diagnostic / Biomarker | Diagnostics Leaders | Intestinal Ischemia | PK/PD & ELISA Development (Need cross-reactive antibodies and pure antigens) |